Search results
Results from the WOW.Com Content Network
Masimirembwa was born in 1967 in Zimbabwe [5] and received his BSc (Hons) and DPhil degrees in Biochemistry from the University of Zimbabwe in 1993. [6] Fascinated by the then-emerging field of pharmacogenetics, he conducted studies at the Karolinska Institute in Sweden in 1995, [5] where he earned his PhD in Medical Biochemistry and Biophysics.
AstraZeneca's primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index; it also has a secondary listing on the Nasdaq Stockholm. It is also listed on the American Nasdaq and is a Nasdaq-100 company. AstraZeneca has one of the highest market capitalisations of pharmaceutical companies worldwide. [12]
The consolidation of AstraZeneca's global R&D footprint will have an impact on sites in the United States. About 1,200 positions will leave Wilmington, while there will be an increase of about 300 ...
The doctoral training programme entitled International PhD Programme in Molecular Medicine was launched in October 2005, and, in 2006, established as central facility of Ulm University as “Graduate School in Molecular Medicine”. [11] [12] From 2007 until 2019, IGradU was supported by the DFG (German Research Foundation). [13]
He previously held the role of Executive Vice President, Innovative Medicines & Early Clinical Development (IMED) Biotech Unit of AstraZeneca from April 2010 to December 2018. Since Pangalos has been working at AstraZeneca, the company's compound success rate from pre-clinical studies to launch has increased from 4% to >19%. [13]
Jane Osbourn, OBE, is a scientist and former chair of the UK BioIndustry Association. [1]A Natural Sciences graduate of Queens' College, Cambridge, Osbourn completed several post-graduate qualifications before moving into industry at Cambridge Antibody Technology, that became MedImmune and AstraZeneca.
Alexion Pharmaceuticals was founded in 1992 at Science Park in New Haven, Connecticut by Steven Squinto and Leonard Bell, a physician at Yale New Haven Hospital and assistant professor of medicine and pathology at Yale School of Medicine.
In August 2012 he was named as the new chief executive of AstraZeneca, [9] the world's fifth largest pharmaceutical company, when aged 53. He took up the post on 1 October 2012. He took up the post on 1 October 2012.